A new topical therapy (L2ASOCLE) for treating cutaneous lupus erythematosus (CLE)
Official title: A novel therapeutic, L2ASOCLE, for treating cutaneous lupus erythematosus (CLE)
Funded at L2 Diagnostics, LLC · NIH-11409672 · Data updated 2026-11-12
A first‑in‑class topical treatment called L2ASOCLE targets a key molecule involved in CLE to reduce skin inflammation and damage.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | L2 Diagnostics, LLC NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | September 21, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $323,090 |
| NIH project number | 1R41AR087258-01A1 |
| Project ID | NIH-11409672 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with cutaneous lupus erythematosus who have active skin inflammation and scarring risk, and who could participate in early safety and efficacy studies.
✕Less likely to help
Patients without CLE or with inactive disease are unlikely to benefit from this topical treatment.
What this research studies
CLE is a chronic autoimmune skin disease that can cause persistent redness, swelling, and scarring that affects daily life. This project tests a topical drug called L2ASOCLE that blocks a run of genetic instructions (HIF-1α) believed to drive CLE in preclinical models. The work includes examining how well the treatment reaches the skin, how safe it is, and whether it lowers inflammatory signals and tissue damage in lab and animal systems. If the results are favorable, they will support moving toward later human studies to help people with CLE.
Why it matters
Potential benefit: If successful, L2ASOCLE could become a skin-directed therapy that reduces inflammation and scarring in CLE patients.
How similar studies have gone: Previous research in related autoimmune skin conditions suggests that targeting specific molecular pathways can reduce inflammation and tissue damage, making this approach promising but still early.
Where this research is happening
-
L2 Diagnostics, LLC
New Haven, United States Active
Researchers
- Principal investigator: Karatepe, Kutay — L2 Diagnostics, LLC
- Study coordinator: Karatepe, Kutay
Related research
Other NIH-funded projects on the same topics.
-
Understanding how DIS3L2 helps keep RNA in check to help lupus patients
A physician-scientist team is studying how a watchdog molecule for RNA (DIS3L2) may drive lupus-related immune problems, with the goal of uncovering new paths to treatment.
-
Pathogenic T cells in discoid lupus erythematosus
A doctor-scientist at Yale is studying why certain immune T cells cause skin damage in discoid lupus, with the goal of finding ways to reduce scarring and improve health for patients, especially African American women.
-
Glycoprotein urine markers that signal lupus nephritis treatment response
A novel test uses urine glycoprotein patterns to show how well lupus nephritis is responding to standard treatment.
-
Immunostimulatory short non-coding RNAs and lupus
A study in people with lupus looks at tiny RNA pieces that may spark inflammation, to understand if they drive disease activity.
-
Antiviral factors that limit HIV in people with SLE
Researchers at Howard University are studying how immune factors in people with lupus may help limit HIV infection.
-
PTPRS and lupus nephritis: a new target to reduce kidney damage in lupus
Aims to understand how PTPRS contributes to kidney inflammation and scarring in lupus nephritis and explore targeting it to help patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.